A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a phase II study.

A new precision radiotherapy technique described as ‘practice changing’ has been shown to reduce long-term side effects, including swallowing problems, for patients with head and neck cancer following treatment.

A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.